Diabetic kidney disease
Therapeutic area
Metabolic Disease
Rare disease
No
- Definition
- Progressive kidney disorder caused by vascular damage to the glomerular capillaries, in patients with diabetes mellitus. It is usually manifested with nephritic syndrome and glomerulosclerosis.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Diabetic kidney disease
- Therapeutic area
- Metabolic Disease
- diabetic kidney disease
- DKD
- diabetic nephropathy
- type 1 diabetes nephropathy
- type 2 diabetes nephropathy
- Severity
- Severe
- Metabolic Disease
- Nephrology
- MONDO ID
- MONDO:0005016
- Parent condition
- MONDO:0005066
Related records
Broader conditions (8)
- Chronic kidney disease
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Human disease
- Kidney disorder
- Metabolic disease
- Urinary system disorder
Trials (342)
- "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD With Type 2 Diabetes"
- "Residual Kidney Function and Oxidative Stress in Incremental vs Standard Peritoneal Dialysis (2 Mexican Centers)"
- 6-Month Safety And Efficacy Study Of TTP488 In Patients With Type 2 Diabetes And Persistent Albuminuria
- A Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy
- A Cohort Study on the Efficacy of Bariatric Surgery for Rapidly Progressing Diabetic Nephropathy
- A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease
- A Long-Term Follow-Up Study of Participants Exposed to REACT
- A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
- A Phase 2b Diabetic Kidney Disease Study
- A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study
- A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
- A Study in Participants With Diabetic Kidney Disease
- A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
- A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors
- A Study of Participants With Chronic Kidney Disease Previously Treated With REACT
- A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria
- A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria
- A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR
- A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
- A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
Approved drugs (2)
- Captopril
- Irbesartan
Drugs in development (80)
- Aliskiren Phase 2
- Atrasentan Phase 3
- Avosentan Phase 3
- Azeliragon Phase 2
- Bardoxolone methyl Phase 3
- Baricitinib Phase 2
- Bindarit Phase 2
- BMS-813160 Phase 2
- Calcitriol Phase 3
- Calcium carbonate Phase 2
- Canagliflozin Phase 3
- Colchicine Phase 2
- Corticotropin Phase 2
- Dapagliflozin Phase 2
- Defibrotide Phase 3
- Dimesna Phase 3
- Duloxetine Phase 2
- Empagliflozin Phase 3
- Eplerenone Phase 2
- Fenofibrate Phase 2
Other linked drugs (14)
- Allopurinol
- Beraprost sodium
- Celecoxib
- Furosemide
- Gemigliptin
- Henagliflozin
- Ilepatril
- Losartan potassium
- Minocycline
- Oxygen
- Recombinant human kallikrein-1
- Rinvecalinase alfa
- Solizmestrocel
- Valziflocept